Analyzing MusclePharm (OTCMKTS:MSLP) & Rani Therapeutics (NASDAQ:RANI)
Analyzing MusclePharm (OTCMKTS:MSLP) & Rani Therapeutics (NASDAQ:RANI)
MusclePharm (OTCMKTS:MSLP – Get Rating) and Rani Therapeutics (NASDAQ:RANI – Get Rating) are both small-cap consumer staples companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.
穆斯克萊帕姆(場外交易代碼：MSLP-GET評級)和拉尼治療公司(納斯達克：RANI-GET評級)都是小型消費品公司，但哪一家更好？我們將根據這兩家公司的收益、股息、估值、機構所有權、盈利能力、風險和分析師的建議來比較它們的實力。
Institutional and Insider Ownership
機構和內部人持股
15.5% of MusclePharm shares are held by institutional investors. Comparatively, 6.4% of Rani Therapeutics shares are held by institutional investors. 60.7% of MusclePharm shares are held by company insiders. Comparatively, 52.3% of Rani Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
該公司15.5%的股份由機構投資者持有。相比之下，Rani治療公司6.4%的股份由機構投資者持有。MusclePharm 60.7%的股份由公司內部人士持有。相比之下，Rani治療公司52.3%的股份由公司內部人士持有。強大的機構持股表明，大型基金管理公司、對衝基金和捐贈基金相信，一家公司有望實現長期增長。
Earnings and Valuation
收益和估值
This table compares MusclePharm and Rani Therapeutics' revenue, earnings per share and valuation.
下表比較了MusclePharm和Rani治療公司的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MusclePharm | $50.04 million | 0.00 | -$12.87 million | ($0.58) | 0.00 |
| Rani Therapeutics | $2.72 million | 107.98 | -$8.33 million | ($1.20) | -4.96 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 穆斯克爾帕姆 | 5,004萬美元 | 0.00 | -1287萬美元 | ($0.58) | 0.00 |
| 拉尼治療公司 | 272萬美元 | 107.98 | -833萬元 | ($1.20) | -4.96 |
Rani Therapeutics has lower revenue, but higher earnings than MusclePharm. Rani Therapeutics is trading at a lower price-to-earnings ratio than MusclePharm, indicating that it is currently the more affordable of the two stocks.
Rani治療公司的收入較低，但比MusclePharm的收入高。Rani Treateutics的市盈率低於MusclePharm，這表明它目前是兩隻股票中更負擔得起的一隻。
Analyst Ratings
分析師評級
This is a summary of recent recommendations and price targets for MusclePharm and Rani Therapeutics, as reported by MarketBeat.com.
據MarketBeat.com報道，這是MusclePharm和Rani治療公司最近的建議和價格目標的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MusclePharm | 0 | 0 | 0 | 0 | N/A |
| Rani Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 穆斯克爾帕姆 | 0 | 0 | 0 | 0 | 不適用 |
| 拉尼治療公司 | 0 | 0 | 3 | 0 | 3.00 |
Rani Therapeutics has a consensus target price of $22.00, suggesting a potential upside of 269.75%. Given Rani Therapeutics' higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than MusclePharm.
Rani Treateutics的共識目標價為2200美元，暗示潛在上漲269.75%。考慮到Rani治療公司更有可能上行，分析師們顯然認為Rani治療公司比MusclePharm更有利。
Profitability
盈利能力
This table compares MusclePharm and Rani Therapeutics' net margins, return on equity and return on assets.
此表比較了MusclePharm和Rani治療公司的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| MusclePharm | -38.51% | N/A | -169.56% |
| Rani Therapeutics | N/A | -25.86% | -23.88% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 穆斯克爾帕姆 | -38.51% | 不適用 | -169.56% |
| 拉尼治療公司 | 不適用 | -25.86% | -23.88% |
Risk and Volatility
風險和波動性
MusclePharm has a beta of -0.07, suggesting that its share price is 107% less volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.
MusclePharm的貝塔係數為-0.07，這表明其股價的波動性比標準普爾500指數低107%。相比之下，Rani Treateutics的貝塔係數為0.52，這表明其股價的波動性比標準普爾500指數低48%。
Summary
摘要
Rani Therapeutics beats MusclePharm on 7 of the 13 factors compared between the two stocks.
Rani治療公司在兩隻股票之間進行比較的13個因素中有7個超過了MusclePharm。
About MusclePharm
關於MusclePharm
(Get Rating)
(獲取評級)
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.
公司在美國和國際上開發、製造、營銷和分銷運動營養品和營養補充劑。該公司提供一系列高性能粉末、膠囊、片劑、凝膠和隨時可用的零食。該公司的MusclePharm品牌產品組合包括戰鬥蛋白粉和戰鬥擠壓蛋白棒；以及支鏈氨基酸、肌酸、谷氨醯胺、肉鹼、共軛亞油酸、魚油、多種維生素和其他產品等基本補充劑。該公司還提供FitMisse品牌的運動營養產品，這些產品主要是為女性身體制定的，以支持女性在體重管理、瘦肌肉質量、身體成分以及一般健康和健康方面的需求；以及FitMisse Energy和FitMisse Energy品牌的功能能量飲料。它向各種運動員和健身愛好者銷售其產品。該公司成立於2006年，總部設在內華達州拉斯維加斯。
About Rani Therapeutics
關於Rani治療公司
(Get Rating)
(獲取評級)
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Rani治療控股公司是一家臨牀階段的生物治療公司，開發口服生物製劑。該公司開發了RaniPill膠囊，這是一個旨在用口服劑量取代皮下或靜脈注射生物製品的平臺。其產品線包括用於治療神經內分泌腫瘤和肢端肥大症的奧曲肽RT-101，用於治療神經內分泌腫瘤和肢端肥大症的第一階段臨牀試驗；用於治療牛皮癬關節炎的抗腫瘤壞死因子-α抗體RT-105；用於治療骨質疏鬆症的甲狀旁腺激素RT-102；用於治療生長激素缺乏的人類生長激素RT-109；用於治療甲狀旁腺功能減退症的甲狀旁腺激素RT-110；以及用於治療2型糖尿病的基礎胰島素RT-106。該公司成立於2012年，總部位於加利福尼亞州聖何塞。
Receive News & Ratings for MusclePharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MusclePharm and related companies with MarketBeat.com's FREE daily email newsletter.
接受MusclePharm日報的新聞和評級-在下面輸入您的電子郵件地址，即可通過MarketBeat.com的免費每日電子郵件時事通訊收到對MusclePharm和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。